<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00512005</url>
  </required_header>
  <id_info>
    <org_study_id>030301</org_study_id>
    <nct_id>NCT00512005</nct_id>
  </id_info>
  <brief_title>VIVID - Valvular and Ventricular Improvement Via iCoapsys Delivery - Feasibility Study</brief_title>
  <acronym>VIVID</acronym>
  <official_title>Valvular and Ventricular Improvement Via iCoapsys Delivery (VIVID) Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Myocor</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Myocor</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this prospective, non-randomized, single-arm feasibility study is to evaluate
      safety and feasibility of the iCoapsys System in patients with functional mitral valve
      insufficiency caused by annular dilation and/or papillary muscle displacement.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Functional MR is a frequent outcome of ischemic heart disease or dilated cardiomyopathy.
      Patients with functional MR generally have normal valvular structures complicated by left
      ventricular dysfunction. Left ventricular dysfunction will often create geometric distortions
      that prevent complete leaflet coaptation, rendering the valve incompetent. Changes that will
      induce functional MR may include (i) dyskinetic or akinetic wall segments, (ii) dilation of
      the valve annulus or (iii) dilation of the left ventricle leading to tethering of the chordae
      tendinae.

      The iCoapsys Device is intended to treat patients with functional MR. The device is not
      indicated for patients with diseased or damaged valvular structures caused by rheumatic
      fever, degenerative diseases, endocarditis, infiltrative diseases or congenital disorders.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2008</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intra-procedural implant safety of iCoapsys System, Peri-procedural safety of the iCoapsys System, Intra-procedural MR reduction with the iCoapsys System</measure>
    <time_frame>Intra-procedure and peri-procedure</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Minnesota Living with Heart Failure Questionnaire, 6-Minute Hallwalk, LV Chamber Volumes</measure>
    <time_frame>1, 3, 6, 12, 18, 24 months and annually thereafter</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Mitral Valve Regurgitation</condition>
  <condition>Left Ventricular Dysfunction</condition>
  <condition>Heart Failure</condition>
  <condition>Mitral Insufficiency</condition>
  <condition>Mitral Incompetence</condition>
  <condition>Ischemic Heart Disease</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Percutaneous mitral valve repair</intervention_name>
    <description>Ventricular reshaping to treat functional mitral insufficiency</description>
    <other_name>iCoapsys System</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Grade 3 or 4 functional mitral valve regurgitation per 2D echocardiography.

          -  NYHA Class II and LVEF greater than or equal to 25% or NYHA Class III and LVEF greater
             than or equal to 30%

        Key Exclusion Criteria:

          -  History of pericarditis.

          -  Creatinine &gt; 2.2 at the time of the procedure

          -  INR &gt; 1.8 at the time of the procedure

          -  Prior pericardial intervention (including CABG, pericardiotomy or pericardiocentesis).

          -  Any endovascular therapeutic interventional or surgical procedure performed within 30
             days prior to the index procedure (e.g., stent placement).

          -  Any planned therapeutic interventional or surgical procedure planned within 30 days
             following the index procedure

          -  Open chest surgery contraindication (e.g., acute respiratory distress, endocarditis,
             myocarditis).

          -  Structural abnormality of the mitral valve

          -  Valve disease resulting in insufficiency or stenosis of the aortic, pulmonary or
             tricuspid valve requiring intervention.

          -  Pericardial effusion &gt;5 mm via echocardiography.

          -  Posterior wall end-diastolic dimension &gt;1.3 cm.

          -  Left ventricular end diastolic diameter &gt; 7.0 cm.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Cyril J. Schweich, MD</last_name>
    <phone>763 494 5400</phone>
    <email>schweich@myocor.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Adam K Hoyhtya, MS</last_name>
    <phone>763 494 5430</phone>
    <email>hoyhtya@myocor.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pamela Hyde, RN</last_name>
      <phone>404-712-7665</phone>
      <email>Pamela.hyde@emoryhealthcare.org</email>
    </contact>
    <investigator>
      <last_name>Peter Block, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Evanston Northwestern Healthcare - Evanston Hospital</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia Focks</last_name>
      <phone>847-570-2366</phone>
      <email>cfocks@enh.org</email>
    </contact>
    <investigator>
      <last_name>Theodore Feldman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shawnee Mission Hospital</name>
      <address>
        <city>Shawnee Mission</city>
        <state>Kansas</state>
        <zip>66204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Millie Salkind</last_name>
      <phone>913-671-6516</phone>
      <email>msalkind@kcheart.com</email>
    </contact>
    <investigator>
      <last_name>Paul Kramer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Abbott Northwestern Hospital</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55440</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Olson, RN</last_name>
      <phone>612-863-7601</phone>
      <email>sara.olson@allina.com</email>
    </contact>
    <investigator>
      <last_name>Wesley Pedersen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 6, 2007</study_first_submitted>
  <study_first_submitted_qc>August 6, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2007</study_first_posted>
  <last_update_submitted>June 23, 2009</last_update_submitted>
  <last_update_submitted_qc>June 23, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2009</last_update_posted>
  <responsible_party>
    <name_title>Cyril J. Schweich, MD / VP of Clinical and Regulatory Affairs</name_title>
    <organization>Myocor, Inc.</organization>
  </responsible_party>
  <keyword>Functional Mitral Regurgitation (FMR)</keyword>
  <keyword>Ischemic Mitral Regurgitation</keyword>
  <keyword>Less invasive repair</keyword>
  <keyword>Percutaneous MV repair</keyword>
  <keyword>Mitral Valve Repair</keyword>
  <keyword>Heart Failure</keyword>
  <keyword>Left Ventricular Dysfunction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Ventricular Dysfunction</mesh_term>
    <mesh_term>Ventricular Dysfunction, Left</mesh_term>
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

